Rabbit Polyclonal Phospho-Insulin R (T1375) antibody (STJ90582)

$99.00$319.00

Reactivity: Human, Mouse, Rat
Applications: WB, IHC, ELISA
Conjugation: Unconjugated
Supplier: St John’s Laboratory Ltd.

Clear
-$50 as credit for submitting review for primary antibody
Shipping notice:
Product will be delivered in 6 to 8 Business Days

Rabbit Polyclonal Phospho-Insulin R (T1375) antibody (STJ90582)

Supplier: St John’s Laboratory Ltd.

Recommended applications: WB, IHC, ELISA

Recommended dilution: WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:5000;

Recommended protocols: check protocols

Image descriptions:

Click or hover above images to see image description for Insulin R (phospho Thr1375) Polyclonal Antibody.

Alternative names:

Check alternative names for the antibody

Expand

INSR antibody,|CD220 antibody|HHF5 antibody|human insulin receptor antibody|Insr antibody|INSR_HUMAN antibody|Insulin receptor subunit beta antibody|IR 1 antibody|IR antibody|IR-1 antibody|IR1 antibody|Phospho anti-Insulin Receptor (Y1361) antibody (ab60946)
SCBT cat No: sc-57343|sc-7953|sc-57344|sc-710|sc-31366|sc-81465|sc-09|sc-135949|sc-81466|sc-711|sc-373975|sc-57342|sc-31367|sc-31369|sc-20739|sc-74506|sc-133251|sc-74505|

 

Name

Insulin R (phospho Thr1375) Polyclonal Antibody

Catalogue No.

STJ90582

Reactivity

Human, Mouse, Rat

Specificity

Phospho-Insulin R (T1375) Polyclonal Antibody detects endogenous levels of Insulin R protein only when phosphorylated at T1375.

Immunogen

Synthesized phospho-peptide derived from Insulin R (phospho Thr1375) at AA range 1300-1380

Host

Rabbit

Applications

WB, IHC, ELISA

Recommended dilution

WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:5000;

Clonality

Polyclonal

Conjugation

Unconjugated

Isotype

IgG

Molecular weight

130 kDa

Formulation

Insulin R (phospho Thr1375) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Concentration

1 mg/ml

Purification

Insulin R (phospho Thr1375) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Storage

-20 Celsius degree. Avoid repeated freeze/thaw cycles.

Alternative antibody names

Insulin receptor antibody, IR antibody, CD antigen CD220 antibody

Database links

Human UniProt/Swiss-Prot:P06213;Mouse UniPort/Swiss-Prot: P15208;Rat UniProt/Swiss-Port: T2CB11;Human Entrez Gene: 3643;Mouse Entrez Gene: 16337;Rat Entrez Gene: Rn.9876

Protein names

Insulin receptor , IR , CD antigen CD220

Protein function

Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. / ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. / Activated in response to insulin. Autophosphorylation activates the kinase activity. PTPN1, PTPRE and PTPRF dephosphorylate important tyrosine residues, thereby reducing INSR activity. Inhibited by ENPP1. GRB10 and GRB14 inhibit the catalytic activity of the INSR, they block access of substrates to the activated receptor. SOCS1 and SOCS3 act as negative regulators of INSR activity, they bind to the activated INRS and interfere with the phosphorylation of INSR substrates.

Protein tissue specificity

Isoform Long and isoform Short are predominantly expressed in tissue targets of insulin metabolic effects: liver, adipose tissue and skeletal muscle but are also expressed in the peripheral nerve, kidney, pulmonary alveoli, pancreatic acini, placenta vascular endothelium, fibroblasts, monocytes, granulocytes, erythrocytes and skin. Isoform Short is preferentially expressed in fetal cells such as fetal fibroblasts, muscle, liver and kidney. Found as a hybrid receptor with IGF1R in muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at protein level). Overexpressed in several tumors, including breast, colon, lung, ovary, and thyroid carcinomas.

Involvement in disease

Rabson-Mendenhall syndrome (RMS) [MIM:262190]: Severe insulin resistance syndrome characterized by insulin-resistant diabetes mellitus with pineal hyperplasia and somatic abnormalities. Typical features include coarse, senile-appearing facies, dental and skin abnormalities, abdominal distension, and phallic enlargement. Inheritance is autosomal recessive. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Leprechaunism (LEPRCH) [MIM:246200]: Represents the most severe form of insulin resistance syndrome, characterized by intrauterine and postnatal growth retardation and death in early infancy. Inheritance is autosomal recessive. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Diabetes mellitus, non-insulin-dependent (NIDDM) [MIM:125853]: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body’s own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. . Note: The gene represented in this entry may be involved in disease pathogenesis.; Familial hyperinsulinemic hypoglycemia 5 (HHF5) [MIM:609968]: Familial hyperinsulinemic hypoglycemia [MIM:256450], also referred to as congenital hyperinsulinism, nesidioblastosis, or persistent hyperinsulinemic hypoglycemia of infancy (PPHI), is the most common cause of persistent hypoglycemia in infancy and is due to defective negative feedback regulation of insulin secretion by low glucose levels. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Insulin-resistant diabetes mellitus with acanthosis nigricans type A (IRAN type A) [MIM:610549]: Characterized by the association of severe insulin resistance (manifested by marked hyperinsulinemia and a failure to respond to exogenous insulin) with the skin lesion acanthosis nigricans and ovarian hyperandrogenism in adolescent female subjects. Women frequently present with hirsutism, acne, amenorrhea or oligomenorrhea, and virilization. This syndrome is different from the type B that has been demonstrated to be secondary to the presence of circulating autoantibodies against the insulin receptor. . Note: The disease is caused by mutations affecting the gene represented in this entry.

Protein sequence and domain

The tetrameric insulin receptor binds insulin via non-identical regions from two alpha chains, primarily via the C-terminal region of the first INSR alpha chain. Residues from the leucine-rich N-terminus of the other INSR alpha chain also contribute to this insulin binding site. A secondary insulin-binding site is formed by residues at the junction of fibronectin type-III domain 1 and 2. / Belongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily. / Contains 3 fibronectin type-III domains. / Contains 1 protein kinase domain.

Protein post-translational modifications

After being transported from the endoplasmic reticulum to the Golgi apparatus, the single glycosylated precursor is further glycosylated and then cleaved, followed by its transport to the plasma membrane. / Autophosphorylated on tyrosine residues in response to insulin. Phosphorylation of Tyr-999 is required for binding to IRS1, SHC1 and STAT5B. Dephosphorylated by PTPRE at Tyr-999, Tyr-1185, Tyr-1189 and Tyr-1190. Dephosphorylated by PTPRF and PTPN1. Dephosphorylated by PTPN2; down-regulates insulin-induced signaling.

Protein cellular localization

Cell membrane; Single-pass type I membrane protein

Research area

All research areas>Membrane Receptors>insulin R
(View all antibody categories related to Membrane Receptors)

Note

AntibodyPlus can customize Insulin R (phospho Thr1375) Antibody according to your requirement, including bulk product size,etc. Please contact info@antibodyplus.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.

Supplier

St John’s Laboratory Ltd.

Product type

Primary antibody

Reviews


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review

There are no reviews for this product yet.
By submitting a review, get following benefits:

1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!

view database submit reviews

There is no extra validation for this product yet.
Check other extra validated antibodies below:



Welcome to AntibodyPlus!